Compare KMI & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KMI | BDX |
|---|---|---|
| Founded | 1936 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5B | 55.5B |
| IPO Year | 2011 | 1962 |
| Metric | KMI | BDX |
|---|---|---|
| Price | $31.03 | $207.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $31.92 | ★ $207.13 |
| AVG Volume (30 Days) | ★ 16.0M | 2.0M |
| Earning Date | 01-21-2026 | 02-09-2026 |
| Dividend Yield | ★ 3.84% | 2.00% |
| EPS Growth | ★ 17.47 | N/A |
| EPS | 1.37 | ★ 5.82 |
| Revenue | $16,937,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $4.70 | $3.16 |
| Revenue Next Year | $5.61 | $3.12 |
| P/E Ratio | ★ $22.19 | $36.09 |
| Revenue Growth | ★ 12.17 | 8.24 |
| 52 Week Low | $23.94 | $162.29 |
| 52 Week High | $30.59 | $239.24 |
| Indicator | KMI | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 70.23 | 54.17 |
| Support Level | $29.54 | $199.00 |
| Resistance Level | $30.56 | $213.08 |
| Average True Range (ATR) | 0.67 | 5.43 |
| MACD | 0.10 | 0.06 |
| Stochastic Oscillator | 96.70 | 58.25 |
Kinder Morgan operates natural gas, crude oil, and refined products pipelines connecting producing regions to demand centers. It is principally involved in the gathering, storage, and transmission of natural gas across the continental United States. It also operates distribution centers for refined products along with the largest fleet of Jones Act-compliant tankers.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.